Highlights and Quick Summary
- Share Based Compensation of Revenue for the quarter ending September 30, 2023 was 0.0% (a NaN% decrease compared to previous quarter)
- Year-over-year quarterly Share Based Compensation of Revenue decreased by NaN%
- Annual Share Based Compensation of Revenue for 2022 was 0.0% (a NaN% decrease from previous year)
- Annual Share Based Compensation of Revenue for 2021 was 0.0% (a -100.0% decrease from previous year)
- Twelve month Share Based Compensation of Revenue ending September 30, 2023 was 0.0% (a NaN% decrease compared to previous quarter)
- Twelve month trailing Share Based Compensation of Revenue decreased by NaN% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% |
Visit stockrow.com/PRME
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Share Based Compensation of Revenue of Prime Medicine, Inc.
Most recent Share Based Compensation of Revenueof PRME including historical data for past 10 years.Interactive Chart of Share Based Compensation of Revenue of Prime Medicine, Inc.
Prime Medicine, Inc. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | 0.0% | 0.0% | 0.0% | – | – |
| 2022 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 2021 | – | – | – | 0.0% | 0.0% |
| 2020 | – | – | – | – | 7.5% |
Business Profile of Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology